Physician profile
Tanielle B Smith
NPI 1043690894
$1,826.90
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $328 · 2021: $344 · 2022: $250 · 2023: $24.36 · 2024: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $167.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $999.52 | 2019-2024 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $195.66 | 2019-2021 | |
| Lilly USA, LLC | $130.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $108.37 | 2022 | |
| Sanofi-Aventis U.S. LLC | $53.53 | 2020-2021 | |
| Boston Scientific Corporation | $51.95 | 2022 | |
| Scilex Pharmaceuticals INC. | $47.31 | 2019 | |
| Medtronic, INC. | $38.91 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.88 | 2020-2021 | |
| Glaxosmithkline, LLC. | $25.23 | 2020-2021 | |
| W. L. Gore & Associates, INC. | $24.36 | 2023 | Gore Enform Preperitoneal Biomaterial |
| Reshape Lifesciences INC. | $22.24 | 2021 | |
| Genzyme Corporation | $22.01 | 2024 | |
| Pfizer INC. | $21.25 | 2021 | |
| Redhill Biopharma INC. | $19.53 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $16.64 | 2022 | |
| Apollo Endosurgery US INC | $15.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanielle Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.